Skip to main
TYRA

Tyra Biosciences (TYRA) Stock Forecast & Price Target

Tyra Biosciences (TYRA) Analyst Ratings

Based on 10 analyst ratings
Strong Buy
Strong Buy 60%
Buy 40%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Tyra Biosciences is a clinical-stage biotechnology company focused on developing precision medicines for targeted oncology and genetically defined conditions using their in-house precision medicine platform, SNAP. With promising drug candidates in their product pipeline and a strong focus on tackling the toxicity and resistance issues associated with first-generation pan-FGFR inhibitors, the company has the potential for success in the market. Additionally, the company's collaboration revenue, discounted cash flow-based valuation, and solid probability of approval for their drug candidates add further support to their positive outlook. However, risks to their price target achievement include potential issues with response maturation, safety events, and insufficient durability or recurrence control. Investors should monitor updates on the program's progress and longer-term data to assess the potential for long-term value creation.

Bears say

Tyra Biosciences is facing potential issues with their new precision medicine platform, SNAP, as their current clinical-stage drug candidates are struggling to demonstrate strong efficacy and tolerability. Furthermore, the company's path to restoring confidence may be hindered by inconsistent dose-level efficacy and potential safety events. With a P/E of over 30 and a relatively high discount rate, there may be an overvaluation of the company's stock, making it a risky investment option.

Tyra Biosciences (TYRA) has been analyzed by 10 analysts, with a consensus rating of Strong Buy. 60% of analysts recommend a Strong Buy, 40% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Tyra Biosciences and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Tyra Biosciences (TYRA) Forecast

Analysts have given Tyra Biosciences (TYRA) a Strong Buy based on their latest research and market trends.

According to 10 analysts, Tyra Biosciences (TYRA) has a Strong Buy consensus rating as of Sep 18, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $49.30, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $49.30, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Tyra Biosciences (TYRA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.